Shots:
- Samsara Biocapital is a California-based venture capital and registered investment adviser investing across early to post-IPO stages in healthcare, life sciences, oncology, and digital health, with a portfolio of 70+ companies including Scholar Rock and PepGen
- The firm made 30 investments across PIPE (43%), Series B (23%), and other rounds, with notable deals such as $259M in Alumis, $240M in Nkarta, and $225M in DELFI Diagnostics, totalling ~$3.8B invested across four quarters in 2024
- Key therapeutic areas include autoimmune, oncology, cardiovascular, endocrine, and neurologic diseases, while technological focus spans AI/ML, antibodies, cell and gene therapies, diagnostics, and immunotherapies.
Welcome to the November edition of Know Your Investor, highlighting visionary investors driving healthcare and life sciences innovation. For a curated report on a specific investor or venture capital firm, connect with us at connect@pharmashots.com
Established in 2016, Samsara Biocapital is a California-based venture capital firm and a registered Investment Adviser (RIA) with a team of scientists, investors, and industry operators focused on early-to late-stage and post-IPO companies developing innovative therapies to improve patient outcomes. The firm primarily invests in US healthcare, life sciences, oncology, and digital health sectors, maintaining a diverse portfolio of over 70 private and public companies, including Scholar Rock, PepGen, and more.
In 2024, Samsara Biocapital participated in five investment rounds comprising PIPE, Series A-C & Series E. Key additions to its portfolio include:
- Nura Bio
- Obsidian Therapeutics
- Neurogene
- Parabilis Medicines
The Firm’s largest single investment in 2024 remained in Alumis, worth $259M
Samsara Biocapital focuses on early-to late-stage and post-IPO companies developing innovative therapies and mainly invests in the US healthcare, life sciences, oncology, and digital health sectors
Therapeutic Areas of Focus (2024):
- Autoimmune
- Oncology
- Cardiovascular
- Dermatology
- Endocrine/Metabolic
- Urology
- Neurologic
- Ophthalmic
Technological Focus (2024):
- Antibodies
- AI/ML
- Cell Therapies
- Diagnostics
- Gene therapies
- Immunotherapies
- Small molecules
- Peptides
- Proteins
- Radiotherapies
In 2024:
- Total Companies Invested In: 30
- PIPE: 43.33% of investments
- Series B: 23.33% of investments
Key Investments in 2024:
- $259M Series C – Alumis
- $240M PIPE – Nkarta
- $225M Series B – DELFI Diagnostic
Quarterly Investments in 2024:
- Q1: 8 investments worth $1165M
- Q2: 7 investments worth $955.5M
- Q3: 7 investments worth $772.9M
- Q4: 8 investments worth $930.65M
The table below depicts the top 5 out of the 30 investments made by Samsara Biocapital:
Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line “Samsara Biocapital” or for early access to complete data for future reports and analysis, register here: https://forms.office.com/r/VwFu6aUm80)
Related Post: Know Your Investor: Samsara Biocapital (October’24 Edition)
